Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDPHV-201401 HIV-1 DNA and Protein Vaccine
NCT03409276Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2018
- Primary completion
- May 2020
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PDPHV-201401 in human immunodeficiency virus infection (HIV) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms, Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms and 3 more. Started Mar 2018; status: completed.
02
Drugs
PDPHV-201401
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03409276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03409276.